Robert W. Baird reaffirmed their hold rating on shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in a report issued on Friday. The brokerage currently has a $2.00 price target on the biopharmaceutical company’s stock.
A number of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Proteon Therapeutics from a strong-buy rating to a hold rating in a report on Wednesday, October 18th. HC Wainwright set a $2.00 price target on shares of Proteon Therapeutics and gave the stock a hold rating in a report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reaffirmed a market perform rating on shares of Proteon Therapeutics in a report on Wednesday, August 16th. Finally, Cowen and Company reaffirmed a hold rating on shares of Proteon Therapeutics in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $6.13.
Shares of Proteon Therapeutics (PRTO) opened at $1.85 on Friday. Proteon Therapeutics has a twelve month low of $1.10 and a twelve month high of $11.45.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC acquired a new position in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up approximately 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 49.93% of the stock is owned by institutional investors and hedge funds.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.